Introduction
Angiogenesis is a critical component in oncogenesis (1). Tumors can promote angiogenesis through the secretion of pro-angiogenic factors such as vascular endothelial growth factor (VEGF and its isoforms) and basic fibroblast growth factor (bFGF) or over-expression of associated receptors: VEGFR, VEGFR2/KDR and NRP2 (2). Tumors utilize this host-mediated process to meet their metabolic needs, to help remove biological waste products of rapidly dividing cells, and to provide a mechanism for metastasis.
Angiogenic factors interact with a multitude of pathways, including matrix metalloproteinases, inflammatory cytokines, chemokines (e.g., interleukins and interferons), integrins, nitric oxide, and other endothelial related proteins. Downstream signalling effectors of angiogenesis receptors also lead to the activation of the phosphatidylinositol 3-kinase/AKT (PI3K-AKT) and mitogen-activated protein kinase (MAPK) pathways.
The VEGF pathway is predominantly driven by host factors. Host genetic variability in this pathway may therefore influence angiogenesis-dependent biological pathways during cancer development and hence influence outcome and sensitivity to various therapies. Associations between genetic polymorphisms in VEGF and the risk of developing various cancers have been reviewed previously (3). Less is known about the role of potential germline polymorphisms as prognostic markers of clinical outcomes or the potential predictive or pharmacogenetic nature of these polymorphisms in relation to drug efficacy and toxicity.
We performed a systematic review and meta-analysis of the role of VEGF pathway polymorphisms as markers of clinical outcome and toxicity in cancer patients. The two aims were: (i) to investigate polymorphisms as pharmacogenetic predictors of drug efficacy and toxicities; and (ii) to investigate polymorphisms as general prognostic indicators of survival, independent of therapy.
Methods

Search Query
We performed a literature search of MEDLINE (host: PubMed) for the period of May 1990 through July 2011 using the keywords and MeSH terms: {"angiogenesis", "VEGF", "VEGFR1", "FLT1", "KDR", "VEGFR2", "FGF2", "FGF", "FGFR", "NRP1", "Endostatin", "VEGFA", "VEGFB", "Bevacizumab"} and "cancer" and "polymorphism". We limited searches to English language articles.
Study Inclusion and Exclusion Criteria
Article eligibility was reviewed independently by 2 reviewers (G.L., L.E.). Eligible articles were original peer-reviewed studies focused on genetic variation in the following angiogenesis pathway genes: VEGFA, VEGFB, and FGF2, and/or genes that code for their direct interactors or receptors: FLT (VEGFR1), KDR (VEGFR2), NRP1 and FGFR. These genes were selected from The Pharmacogenomics Knowledgebase website (4). We also included Endostatin, the 20-kDa C-terminal fragment derived from type XVIII collagen that is a broad spectrum anti-angiogenic factor, which can affect both VEGF and FGF2 pathways and is coded by COL18A1. Eligible studies must have reported cancer outcome (i.e., not risk alone), and may have included either/both prognostic and pharmacogenetic assessments. The outcomes evaluated were of any of the following: overall survival (OS), progression free survival (PFS), time to progression (TTP), time to recurrence (TTR), disease free survival (DFS), response rate (RR), and association with Duplicate studies were excluded as were those testing solely the association of polymorphisms and cancer risk/susceptibility, tumor staging/grading or gene expression. We also excluded case reports, opinion pieces (e.g., letters to the editors) and other review papers. We categorized studies as being pharmacogenetic (effect of polymorphism on response/outcome/toxicity to therapy where treatment included anti-angiogenic therapy) or prognostic (effect of polymorphism on outcome irrespective of therapy); data were analyzed for various disease sites: breast, colorectal, gastro-esophageal, genitourinary, gynecological, lung and other cancers.
Data Extraction and Organization
The following data were extracted from individual publications: title, authors, disease site, country, sample size and/or actual number of patients genotyped, patient inclusion/exclusion criteria, treatment/intervention details, histologic subtypes, grade, stage, tissue used for genotyping (e.g. whole blood versus archival normal tissue) and polymorphisms that were genotyped. Associations between polymorphisms and outcome data were recorded as odds ratios (OR), hazard ratios (HR) or response rate (RR), along with their respective confidence intervals.
We noted whether studies were analyzed using only univariate (or crude) analysis or in multivariate (or adjusted) analysis. Haplotype analyses, if performed, were also recorded. A common problem was the use of different nomenclature and names for the same polymorphism.
Thus, all identified polymorphisms sharing the same RefSNP (rs) numbers were renamed to 
Meta-analysis
Meta-analyses were performed to evaluate the overall prognostic associations of the most commonly evaluated VEGF polymorphisms when there were an adequate number of individual studies reporting similar outcomes to justify such an analysis. Only studies reporting HR for OS were included. Analyses were undertaken separately for each polymorphism and were conducted in two phases. First, study data reporting outcome by wild-type or variant polymorphisms irrespective of zygosity were assessed together (i.e., pooled). Second, data were assessed separately for homozygous and heterozygous genotypes. Differences between homozygous and heterozygous subgroups were assessed using methods described by Deeks et al (6). Data were analyzed using RevMan 5.1 analysis software (The Cochrane Collaboration, Copenhagen, Denmark). Pooled estimates of HR were computed using generic inverse variance and a randomeffects model (7, 8). All statistical tests were two-sided, and statistical significance was defined as P < 0.01, which corrected for multiple statistical testing using the Bonferroni method.
Results
Summary of included and excluded studies
A total of 614 studies were initially identified (Figure 1 ). Of these, 186 were duplicate reports/studies, 130 were related to cancer development risk and 238 further studies were excluded because they did not include at least 25 patients, did not include polymorphisms of interest, or did not assess any pharmacogenetic or prognostic outcomes of interest. Sixty studies met the inclusion criteria and were included in the final analysis.
Most of the included studies had sample sizes of under 150 patients, and were secondary analyses of Phase I/II clinical trials. Other characteristics of included studies are shown in Table   1 . The majority were prognostic (n = 48), which were based primarily on data from case series (n = 33 (69%)). Most pharmacogenetics studies (n = 12) were nested case-control analyses of clinical trials (n = 7 (64%)).
VEGF pathway polymorphisms as predictive markers of bevacizumab efficacy
Nine studies investigated the predictive effect of polymorphisms on response to bevacizumab in numerous cancer sites (Table 2A; additional data in Supplementary Table 2 
VEGF pathway polymorphisms and treatment toxicity
Seven studies investigated bevacizumab toxicity in various cancer sites (9-12, 14, 15, 17).
Three additional studies investigated the predictive effect of VEGF polymorphisms on toxicity of non-VEGF targeting drugs (Table 2B ; additional data in Supplementary Table 3 
VEGF polymorphisms as prognostic biomarkers
Studies that evaluated VEGF pathway polymorphisms as prognostic markers of cancer outcome are described in Supplementary Tables 4-7 (21-68).
VEGF +936C>T was associated with OS, DFS, or TTR in the three largest colorectal cancer studies involving; however, two showed improved outcome by the T allele, while one showed worse outcome by the T allele (27, 29, 32). Among these three studies, the two showing improved outcome by the T allele involved patients from the United States and Greece and both found a strong relationship between carrying at least one A allele in COL18A1 (Endostatin) +4349G>A (alternatively known as D104N) and worse outcome (adjusted hazard ratio (aHR) for TTR, 2.28, 95% CI = 1.26-4.11; P = 0.004), while a larger 239 patient study in distal esophageal and gastroesophageal junction adenocarcinomas found no relationship (35, 39).
Of five breast cancer studies, VEGF polymorphisms, -7C>T and +405G>C, and the KDR polymorphism, +1192A>G, were associated with either OS or DFS in single, unvalidated studies (21, 22, 24). In genitourinary and gynaecologic cancers, associations were either of borderline statistical significance or involved crude, unadjusted analyses, with two exceptions: VEGF +405C/C genotype was associated with poorer OS in a cervical cancer study (n = 199) from Korea; and minor alleles of VEGFC polymorphisms (rs17697305 and rs1485766) were associated with altered OS outcomes in a single ovarian cancer study that evaluated over 1400 polymorphisms across multiple pathways in 325 patients (52, 54). Separate lung cancer studies reported worse survival with VEGF +405G/G, VEGF -1154A/-, and VEGF -460T/T; none being validated (55, 56, 58).
Meta-analyses of Prognostic Studies
Because of the large number of studies (n = 42) evaluating five individual VEGF polymorphisms (VEGF +936C>T, VEGF -460T>C, VEGF -1154G>A, VEGF -2578C>A and VEGF +405G>C; individual details in Supplementary Tables 4-7), meta-analyses were performed separately on these five polymorphisms. When the homozygous and heterozygous polymorphisms were assessed together (i.e., pooled; Table 3A ), the C allele of VEGF +405G>C was found significantly associated with improved OS (HR = 0.74, 95% CI = 0.60-0.91, P = 0.004). The corresponding forest plot is shown in Table 4A . Among studies in the zygosity- (Table 3B) , the same variant of VEGF +405G>C also showed a statistically significant improvement in OS (HR = 0.79, 95% CI = 0.67-0.94, P = 0.007) that was not different by zygosity (Table 4B) without bevacizumab and found two variants (VEGF -2578C>A and -1154G>A) associated with improved OS while two different variants (VEGF +405G>C and -460C>T) were significantly associated with hypertension; the VEGF -1154G>A and -460C>T are, in general, highly linked in the Caucasian population (9). Both the A allele of VEGF -1154G>A, and the C allele of VEGF -460C>T, were associated with improved outcome in two separate pharmacogenetics studies (11, 12). However, these relationships await validation. In the future, comprehensive analyses of polymorphisms in either carefully designed observational studies or in larger Phase III trials of bevacizumab and other VEGF-targeting agents in ovarian, colorectal, breast, and other cancers could be substantially more useful in delineating the role of these polymorphisms as pharmacogenetic markers.
We also reviewed VEGF pathway polymorphisms serving as general prognostic markers of outcome in patients not treated with VEGF-targeted agents. In this analysis, a large number of prognostic studies across many different cancers including ovarian, cervical, lung, breast, colorectal, gastric, esophageal/gastro-esophageal junction, renal, lung and liver cancers focused on five specific VEGF polymorphic variations. A meta-analysis was performed on these polymorphisms, which identified the variant of VEGF +405G>C showing a highly significant prognostic role in improving the survival of cancer patients. As expected, given the varied cancer sites there was heterogeneity across individual studies (I 2 = 72%). However, the use of a pooled analysis and random effects modelling has been particularly useful for identifying significant relationships in the face of heterogeneous data. suggest that the C allele VEGF +405G>C is associated with decreased promoter activity and decreased expression of VEGF, as the C allele reduces binding of the transcription factor, MZF1, which then subsequently reduces gene expression (72) (73) (74) . Hence, the C allele VEGF +405G>C may confer a survival advantage by reducing a tumor's ability to stimulate angiogenesis.
The quality of a systematic review and meta-analysis is partly related to the quality of its underlying studies. The included studies have limitations. First, studies were extremely varied in sample size: some studies had as few as 28 patients and the largest involved over 1100 patients.
Our meta-analyses included weighting based on sample size. Second, most studies used hypothesis-driven candidate approaches, whereby only specific genes and polymorphisms from a selected list were analyzed. This is a common study design and can be most useful for metaanalyses, but suffers from an inability to identify novel biomarkers. Third, statistical significance of the VEGF +405G>C polymorphism for cancer prognosis required the pooling of heterogeneous studies across disease sites that had different underlying populations (i.e., race/ethnicity), study designs, sample sources (i.e., blood versus tumor based tissue), and statistical analyses (including whether there was adjustment for multiple comparisons, and using multivariate versus univariate analyses). However, this heterogeneity has advantages in that the significance of this finding was robust to all these aforementioned issues. Finally, several of the measured phenotypes, such as therapeutic response and drug toxicity, were defined differently across studies, rendering it difficult for cross-comparison, interpretation and evaluation in pooling or meta-analytical analysis. For example, some studies explored each toxicity separately, while other studies analyzed multiple toxicities as a composite measure. Hence, no metaanalyses were performed for the pharamacogenetic arm of the study. 
In conclusion, there have been a large number of published studies exploring the association of germline polymorphisms of the VEGF pathway with cancer outcomes and treatment toxicities. These studies have substantial heterogeneity both in terms of methodology and in terms of effect size. When studies using similar methodology and involving similar outcome were assessed in meta-analyses, the variants of VEGF +405G>C were highly significantly associated with a 26% relative improvement in overall survival across a variety of tumor types, even after accounting for the number of comparisons performed. Future prospective studies should extend this research to include pathway analysis, haplotype analysis and discovery-focused genome-wide association studies, followed by appropriate validation or metaanalytical analyses.
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